TamaFlex from NXT USA awarded composition patent
U.S. Patent #11,147,850, titled: “Synergistic Composition For Osteoarthritis” was awarded in late October.
A new U.S. composition patent has been awarded to NXT USA for its flagship ingredient TamaFlex. U.S. Patent #11,147,850, titled: “Synergistic Composition For Osteoarthritis” was awarded in late October. The invention relates to the synergistic composition of Tamarindus indica seed extract and Curcuma longa rhizome extract for several indications, including inflammation, joint function and collagen breakdown.
“This is a validating event for the researchers that created TamaFlex, for NXT USA, and also for TamaFlex consumers. It is a game-changer that this novel composition is recognized in a US Patent, because it supports the discovery, development and clinical substantiation that backs this exciting new ingredient,” said Eric Anderson, managing director for NXT USA, in a press release.
“TamaFlex is clinically validated in both healthy participants and participants with mild joint discomfort to provide benefits in just five days,” added Anderson. “In comparison, most joint products rely on data from folks with existing health conditions and need extended periods of time to provide efficacy.”
